Dextromethorphan - A harmless cough suppressant?;Dextromethorphan - Ein harmloses hustenmittel?

Deutsche Apotheker Zeitung

Volumn 147, Issue 31, 2007, Pages 42-48

  Röhm, Stephanie ^a   Stürer, Andreas ^b   Pietsch, Jörg ^c   Läer, Stephanie ^a   Uhl, Doris ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Schweizerisches Toxikologisches Informationszentrum   (Switzerland)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; ANTIHISTAMINIC AGENT; COCAINE; DEXTROMETHORPHAN; SEROTONIN UPTAKE INHIBITOR;

AGITATION; ARTICLE; CLINICAL FEATURE; COUGHING; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; EUROPE; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; INTERNET; MEDICAL EXPERT; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; UNITED STATES;

EID: 34548808088     PISSN: 00119857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Erfahrungsbericht mit Dextromethorphan: http://grasstift.blog.de/2007/07/ 03/meinedxm_erfahrungen_oder_heftig_leute~2567397. 3. Juli 2007.
2. Erfahrungsbericht mit Dextromethorphan:http://www.drogenwiki.de/wiki/ index.php/DXM-Erfahrungen_von_W. 3. Juli 2007.
3. Partnership for a drug free AmericaTM: http://www.drugfree.org/Portal/ DrugIssue/Research/Teens_2005/ Generation_Rx_Study_Confirms_Abuse_of_Prescription. 17. Mai 2007.
4. Bryner JK, Wang UK, Hui JW, Bedodo M, MacDougall C, Anderson IB. Dextromethorphan abuse in adolescence: an increasing trend: 1999-2004. Arch Pediatr Adolesc Med 2006;160:1217-1222.
5. FDA warns against abuse of Dextromethorphan: http://www.fda.gov/bbs/ topics/ANSWERS/2005/ANS01360.html. 20. Mai 2005.
6. Fachinformation. Hustenstiller ratiopharm. Stand April 2007.
7. Toxikologisches Informationszentrum. http://www.toxi.ch/ger/welcome.html. 22. Juni 2007.
8. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent Inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-68.
9. Deutsche Gesellschaft für Rechtsmedizin; Abstract V5: http://fjt.rechtsmed-hh.de/progr.pdf. 8. Juni 2007.
10. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-296.
11. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000;20: 246-251.
12. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin Pharmacol Ther 2004;75:386-393.
13. De Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
14. McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, Roots I, Silber BM, Milos PM. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci 2000;2:E33.
15. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.